CYP3A4 and CYP2D6 inhibitory activities of Indonesian medicinal plants.
Thirty samples of Indonesian medicinal plants were analyzed for their capacity to inhibit in vitro metabolism by human cytochrome P450 3A4 (CYP3A4) and CYP2D6 with a radiometric assay. The MeOH-soluble fractions of 25 samples, prepared from water extracts, demonstrated inhibitory activity more than 50% on the metabolism mediated by CYP3A4, and 21 samples on the metabolism mediated by CYP2D6. Among the MeOH-soluble fractions, Piper nigrum leaf showed the highest inhibitory activity against CYP3A4 (91.7%), and Punica granatum against CYP2D6 (98.1%). The water extracts of which MeOH-soluble fraction showed inhibitory activity more than 70% were fractionated with EtOAc. From the EtOAc-soluble fractions, Curcuma heyneana (67.0%), Pi. cubeba (75.0%), Pi. nigrum fruit (84.0%), Pi. nigrum leaf (85.8%), and Zingiber aromaticum (75.3%) demonstrated inhibitory activity more than 50% on the metabolism mediated by CYP3A4, but only Pi. nigrum fruit (72.8%) and Pi. nigrum leaf (69.1%) showed strong inhibitory activity against CYP2D6. For samples that showed more than 70% inhibition, their I[C.sub.50] values were determined. The most potent inhibitory activity against CYP3A4 (I[C.sub.50] value of 25 [micro]g/ml) was found for the extract of Pi. nigrum leaf, while that of Catharanthus roseus showed the most potent inhibitory effect against CYP2D6 (I[C.sub.50] value of 11 [micro]g/ml). These results should indicate once more the possibility of potential medicinal plant-drug interactions.
[c] 2005 Elsevier GmbH. All rights reserved.
Keywords: Cytochrome P450; Jamu; Drug interaction; Inhibition; CYP3A4; CYP2D6
Cytochrome P450 (CYP) is the main enzyme which catalyzes the metabolism of drugs and other xenobiotics. CYP3A4, the major hepatic and intestinal CYP in humans, metabolizes more than 50% of clinically used drugs such as cyclosporine A, dihydropyridines, ethinylestradiol, midazolam, terfenadine, and triazolam (Rendic and DiCarlo, 1997). CYP2D6 catalyzes the metabolism of about 30% of all drugs including amitriptyline, imipramine, haloperidol, propranolol, and dextromethorphan (Clarke and Jones, 2002).
Recently, several reports have demonstrated that natural compounds and herbal products may cause pharmacokinetic interaction with western drugs used clinically when they are simultaneously administrated (Foster et al., 1999; Nebel et al., 1999; Taylor and Wilt, 1999). The use of medicinal herbs has particularly increased over the past few years among specific patient populations including HIV-infected patients. St. John's wort altered pharmacokinetics of the HIV protease inhibitor, indinavir in individuals on retroviral therapy (Piscitelli et al., 2000). Indeed, plasma concentrations of the HIV protease inhibitor, saquinavir, have been decreased in individuals exposed long-term to garlic supplements (Piscitelli et al., 2002). The increased clearance of saquinavir may be due to induction of hepatic and/or intestinal CYP3A4. The most widely studied natural product is grapefruit juice, which has been found to increase the bioavailability and/or to prolong the metabolic elimination of many drugs such as dihydropyridine-type calcium channel blockers, histamine-1 receptor antagonists (e.g., terfenadine), quinidine, benzodiazepines (e.g., midazolam), 17[beta]-estradiol, and caffeine (Ameer and Weintraub, 1997; Bailey et al., 1998).
Indonesia, a country in Southeast Asia, has many medicinal plants which are used as traditional medicines "Jamu" (Sastroamidjojo, 1997). Those medicinal plants have been used from the ancient time to now, and are largely consumed by people of different levels in villages and also in big cities. People could easily buy readymade "Jamu" which is packed in the form of powder, pills, capsules, drinking liquid, and ointment. There are still "Jamu" shops to sell only ingredients or to prepare the "Jamu" on spot by request. It is a common view across the country that some women are roaming the street to sell "Jamu", and many Indonesians start their day with drinking "Jamu". These traditional medicines are almost unregulated, and many patients do not inform their physician about the traditional medicines they consume. Therefore, interactions between traditional medicines and drugs prescribed clinically are becoming a concern. To the best of our knowledge, there have been no reports on the inhibitory potential of Indonesian medicinal plants against CYP. Thus, we chose 30 medicinal plants which are generally used in Indonesian traditional medicines (Sastroamidjojo, 1997; PT Eisai Indonesia, 1995) (Table 1) and evaluated their inhibitory activity against CYP3A4 and CYP2D6.
Materials and methods
Indonesian medicinal plants were obtained at GORO traditional market, Jakarta, Indonesia, in May 2002 and voucher samples are preserved at the Museum of Materia Medica, Research Center for Ethnomedicines, Institute of Natural Medicine, Toyama Medical and Pharmaceutical University, Toyama, Japan (Table 1).
Extraction and preparation of test solutions
Each medicinal plant (25-150 g) was cut into small pieces and extracted with water (150-400 ml, reflux, 2 h, x 2). The water solution was concentrated under reduced pressure and lyophilized to give a water extract. A part of the water extract (0.5 g) from each medicinal plant was extracted with MeOH (15 ml), followed by centrifugation to facilitate removal of the supernatant, to give a MeOH-soluble fraction. The MeOH-soluble fraction was evaporated and redissolved in 1.5 ml of MeOH and used as a test solution. The medicinal plants on which the MeOH-soluble fraction showed strong inhibition against CYP3A4 and/or CYP2D6, an EtOAc-soluble fraction was prepared from the water extract by extracting with EtOAc (15 ml), followed by centrifugation. The EtOAc-soluble fraction was evaporated and dissolved in 1.5 ml of MeOH and used as a test solution.
Quinidine sulfate dihydrate and ketoconazole were obtained from Wako Pure Chemicals Industry, Ltd. (Osaka, Japan). [N-methyl-[.sup.14]C]Erythromycin (55 mCi/mmol, >99% pure) and [O-methyl-[.sup.14]C]dextromethorphan (55 mCi/mmol, >99% pure) were purchased from American Radiolabeled Chemicals, Inc. (St. Louis, MO, USA). Human liver microsomes (HLM) were obtained from Xenotech, LLC (Kansas, KS, USA) and stored at -80 [degrees]C prior to use. [beta]-Nicotinamide adenine dinucleotide phosphate (NAD[P.sup.+], oxidized form), glucose-6-phosphate (G-6-P), and G-6-P dehydrogenase were purchased from Oriental Yeast Co., Ltd. (Tokyo, Japan). All other chemicals and solvents were of the highest grade available.
CYP inhibitory activity
Inhibitory activity against CYP3A4 was assayed by the method of Riley and Howbrook (1998) with a slight modification. Briefly, the assay was performed in a disposable culture tube of 13 x 100 mm (Iwaki, Tokyo, Japan). Tubes were designated as "control", "positive control", and "test". The control tube consisted of 2.5 [micro]l of MeOH; positive control consisted of 2.5 [micro]l of ketoconazole (100 [micro]M); and test tubes consisted of 2.5 [micro]l of samples (equivalent to 1.65 mg/ml of extract). To all tubes were added 150 [micro]l of phosphate buffer (pH 7.4), 197.5 [micro]l of ultrapure water, 50 [micro]l of [N-methyl-[.sup.14]C]erythromycin (0.1 [micro]Ci/incubation, 1 mM in 5% of MeOH), and 50 [micro]l of HLM (4 mg/ml). The total incubation volume was 500 [micro]l. After 5 min preincubation under shaking at 37 [degrees]C, the reaction was initiated by addition of 50 [micro]l of NADPH-generating system (4.20 mg/ml of NAD[P.sup.+], 100 mM of G-6-P, 100 mM of Mg[Cl.sub.2], and 10 U/ml of G-6-P dehydrogenase) and continued for 10 min under the same conditions. The reaction was stopped by the addition of 125 [micro]l of 10% trichloroacetic acid (Nacalai tesque, Inc., Kyoto; Japan). After centrifugation at 3000 rpm for 10 min at room temperature, the supernatant was applied to EnviCarb solid-phase extraction column (Supelco, PA, UK) and was eluted by ultrapure water (500 [micro]l x 2). After addition of 10 ml of Clear-sol I (Nacalai tesque, Inc.), the eluted radioactivity was quantified by liquid scintillation counting LS 6500 (Beckman, CA, USA). Correction was made for radioactivity eluted from the control in which HLM and NADPH-generating system were omitted. The assays were performed in duplicate for all samples. The inhibitory activity against CYP2D6 was also measured by the method of Rodrigues (1996) with a slight modification. The assay was done with the same procedure in the case of CYP3A4 using [O-methyl-[.sup.14]C]dextromethorphan (0.1 [micro]Ci/incubation, 100 [micro]M in 5% of MeOH) as a substrate and longer incubation time (20 min). Quinidine (100 [micro]M) was used as a positive control.
To calculate the I[C.sub.50] values (concentrations of sample causing 50% reduction in activity relative to the control) of the sample that showed more than inhibition 70%, the sample was added to the reaction mixture at a concentration range of 0-1.65 mg/ml. The relationship between the concentration of sample and the remaining activity was analyzed using software product WinNonlin Ver.3.1 (Pharsight Corp., Mountain View, CA, USA). I[C.sub.50] values were calculated by linear regression analysis of the sample concentration versus percentage control activity plots.
[FIGURE 1 OMITTED]
Results and discussion
All 30 samples of Indonesian medicinal plants were analyzed for their ability to inhibit CYP3A4-mediated metabolism of [N-methyl-[.sup.14]C]erythromycin and CYP2D6-mediated metabolism of [O-methyl-[.sup.14]C]-dextromethorphan. The amount of the test solution used was 1.65 mg/ml of extract according to Iwata et al. (2004), or equivalent to 2-10 mg of herbal powder which is 30 times smaller than the minimal amount of one time consumption of Indonesian traditional medicine, generally. The MeOH-soluble fractions of 14 samples (Alyxia reinwardtii, Andrographis paniculata, Curcuma heyneana, Cymbopogon nardus, Glycyrrhiza glabra, Piper cubeba, Pi. nigrum fruit, Pi. nigrum leaf, Pu. granatum, Rheum palmatum, Sanatalum album, Syzygium aromaticum, Tinospora crispa, and Zingiber aromaticum) showed inhibitory activity over 70% on the metabolism mediated by CYP3A4, and Pi. nigrum leaf revealed the strongest activity (91.7%) (Fig. 1). Twelve samples (Alpinia galanga, Alstonia scholaris bark, Amomum compactum fruit, Am. compactum rhizome, Ca. roseus, Cinnamomum burmani, Cu. aeruginosa, Cu. xanthorrhiza, Melaleuca leucodendron, Strychnos ligustrina leaf, St. ligustrina wood, and Z. cassumunar) showed inhibition between 30% and 70%. Other samples showed inhibition only less than 30%.
On the metabolism mediated by CYP2D6, 15 samples (Als. scholaris bark, An. paniculata, Ca. roseus, Ci. burmani, G. glabra, Pi. nigrum fruit, Pi. nigrum leaf, Pu. granatum, R. palmatum, Sa. album, St. ligustrina leaf, St. ligustrina wood, Sy. aromaticum, Ti. crispa, and Z. aromaticum) demonstrated inhibitory activity over 70% and 7 of them were more than 90%: An. paniculata (92.6%), Ca. roseus (96.4%), G. glabra (94.5%), Pi. nigrum leaf (90.9%), Pu. granatum (98.1%), R. palmatum (96.4%), and Sy. aromaticum (94.5%) (Fig. 1). The inhibitory activity more than 30% but less than 70% was found with Aly. reinwardtii, Am. compactum rhizome, Cu. aeruginosa, Cu. heyneana, Cu. xanthorrhiza, Cy. nardus, M. leucodendron, and Pi. cubeba. The remaining samples showed inhibition only less than 30%.
[FIGURE 2 OMITTED]
Then, the EtOAc-soluble fraction was prepared from the water extract whose MeOH-soluble fraction showed inhibition more than 70%. Among 19 EtOAc-soluble fractions, those of Pi. cubeba (75.0%), Pi. nigrum fruit (84.0%), Pi. nigrum leaf (85.8%), and Z. aromaticum (75.3%) demonstrated inhibitory activity over 70% on the metabolism mediated by CYP3A4 (Fig. 2). An. paniculata, Cu. heyneana, and Sy. aromaticum showed the inhibitory activity between 30% and 70%. Other samples showed inhibition only less than 30% against CYP3A4. On the other hand, only Pi. nigrum fruit (72.8%) demonstrated inhibitory activity over 70% on the metabolism mediated by CYP2D6 (Fig. 2), and the inhibition between 30% and 70% was found on Pi. nigrum leaf (69.1%).
The I[C.sub.50] values of the samples that showed inhibition more than 70% are listed in Table 2. All samples showed inhibitory activity on the metabolism mediated by CYP3A4 and CYP2D6 in a concentration-dependent manner. The potent inhibitory activity against CYP3A4 with I[C.sub.50] values less than 100 [micro]g/ml were found on Pi. cubeba (53 [micro]g/ml), Pi. nigrum fruit (29 [micro]g/ml), Pi. nigrum leaf (25 [micro]g/ml), and Pu. granatum (35 [micro]g/ml), while Ca. roseus was the most potent inhibitory activity against CYP2D6 with an I[C.sub.50] value of 11 [micro]g/ml.
These experiments have demonstrated that 63% of the selected samples of Indonesian medicinal plants significantly inhibited CYP3A4-mediated metabolism of [N-methyl-[.sup.14]C]erythromycin and CYP2D6-mediated metabolism of [O-methyl-[.sup.14]C]-dextromethorphan. Tsukamoto et al. (2002) reported five bisalkaloids, dipiperamides A-E, and a lignan, (-)-hinokinin, as potent CYP3A4 inhibitors of Pi. nigrum. In addition, (-)-hinokinin with two methylenedioxyphenyl groups in the molecule was also isolated from Pi. cubeba (Parmar et al., 1997). Methylenedioxyphenyl compounds were well known to inhibit CYP reaction through the formation of stable complexes with CYP enzymes (Marcus et al., 1985). Thus, the inhibitory activity of Pi. cubeba may be due to constituents like (-)-hinokinin. Surprisingly, Pi. nigrum also showed strong inhibition against CYP2D6 (>70%), suggesting the presence of other inhibitor(s). The dried roots of G. glabra have been consumed for the past 6000 years and are used as flavoring and sweating agents, demulcents, and expectorants in the Western world and as antiallergic and anti-inflammatory agents in Japan and China (Chandler, 1985; Mitschner et al., 1986). Licorice root extract, as well as its major isoflavan glabridin, is a potent antioxidant against LDL oxidation in mice and humans (Rosenblat et al., 1999), and Kent et al. (2002) reported that glabridin inactivates CYP3A4 in a time-, concentration-, and NADPH-dependent manner; i.e., mechanism-based inactivation. On the other hand, 2,4-dimethylglabridin did not show the inhibition on CYP3A4. Thus, the two hydroxyl groups on the 2 and 4 positions of the B ring should be important for the CYP3A4 inactivation. In our experiment, G. glabra also showed inhibitory activity over 70% on the metabolism by CYP2D6, indicating the possibility of the presence of other potent inhibitor against CYP2D6.
Fifteen samples from the MeOH-soluble fraction showed inhibitory activity more than 70% on the metabolism by CYP2D6. Hasegawa et al. (2002) identified o-methoxycinnamaldehyde from Cinnamomi cortex as a potent inhibitor against CYP1A2 and CYP2E1 in rat liver microsomes, but they showed weak inhibition against CYP2D6. Thus, CYP2D6-inhibitory constituent(s) in Ci. burmani, showing the inhibition more than 70% on CYP2D6, may be different from o-methoxycinnamaldehyde.
On the EtOAc-soluble fractions, Pi. cubeba, Pi. nigrum, and Z. aromaticum showed strong inhibitory activity on the metabolism by CYP3A4, but only Pi. nigrum inhibited CYP2D6. It should be noted here that Z. aromaticum, showing strong inhibition against CYP3A4, is the crude drug used mostly in Indonesian traditional medicines. The result of this study should clearly demonstrate the probability of interaction between Indonesian medicinal plants and concomitantly administrated conventional drugs. Further studies on these plants, including the identification of the active constituents and in in vivo system, are under progress and will be reported elsewhere.
A part of this work was supported by a Grant-in-Aid for the 21st Century COE Program from the Ministry of Education, Culture, Sports, Science and Technology, Japan.
Ameer, B., Weintraub, R.A., 1997. Drug interactions with grapefruit juice. Clin. Pharmacokinet. 33, 103-121.
Bailey, D.G., Malcolm, J., Arnold, O., Spence, J.D., 1998. Grapefruit juice-drug interactions. Br. J. Clin. Pharmacol. 46, 101-110.
Chandler, R.F., 1985. Licorice, more than just a flavour. Can. Pharm. J. 118, 421-424.
Clarke, S.E., Jones, B.C., 2002. Human cytochromes P450 and their role in metabolism-based drug-drug interactions. In: Rodrigues, A.D. (Ed.), Drug-Drug Interactions. Marcel Dekker, New York, pp. 55-88.
Foster, B.C., Vandenhoek. S., Hanna. J., Akhtar, M.H., Krantis, A., 1999. Effect of natural health products on cytochrome P-450 drug metabolism. Can. J. Infect. Dis. Suppl. 10 (B), 18.
Hasegawa, A., Yoshino, M., Nakamura, H., Ishii, I., Watanabe, T., Kiuchi, M., Ishikawa, T., Ohmori, S., Kitada, M., 2002. Identification of inhibitory component in cinnamon O-methoxycinnamaldehyde inhibits CYP1A2 and CYP2E1. Drug Metab. Pharmacokinet. 17, 229-236.
Iwata, H., Tezuka, Y., Usia, T., Kadota, S., Hiratsuka, A., Watabe, T., 2004. Inhibition of human liver microsomal CYP3A4 and CYP2D6 by extracts from 78 herbal medicines. J. Trad. Med. 21, 42-50.
Kent, U.M., Aviram, M., Rosenblat, M., Hollenberg, P.F., 2002. The licorice root derived isoflavan glabridin inhibits the activities of human cytochrome P450S 3A4, 2B6, and 2C9. Drug Metab. Disp. 30, 709-715.
Marcus, C.B., Murray, M., Wilkinson, C.F., 1985. Spectral and inhibitory interactions of methylenedioxyphenyl and related compounds with purified isozymes of cytochrome P-450. Xenobiotica 15, 351-362.
Mitschner, L.A., Drake, S., Gollapudi, S.R., Harris, J.A., Shankel, D.M., 1986. Isolation and identification of higher plant agents active in antimutagenic assay systems: Glycyrrhiza glabra. In: Shankel, D.M., Hartman, P.E., Kada, T., Hollaender, A. (Eds.), Antimutagenesis and Anticarcinogenesis Mechanism. Plenum Press, New York. pp. 153-165.
Nebel, A., Schneider, B.J., Baker, R.K., Kroll, D.J., 1999. Potential metabolic interaction between St. John's wort and theophylline. Ann. Pharmacother. 33, 502.
Parmar, V.S., Jain, S.C., Bisht, K.S., Jain, R., Taneja, P., Jha, A., Tyagi, O.D., Prasad, A.K., Wengel, J., Olsen, C.E., Boll, P.M., 1997. Phytochemistry of the genus Piper. Phytochemistry 46, 597-673.
Piscitelli, S.C., Burstein, A.H., Chaitt, D., Alfaro, R.M., Falloon, J., 2000. Indinavir concentrations and St. John's wort. Lancet 355, 547-548.
Piscitelli, S.C., Burstein, A.H., Welden, N., Gallicano, K.D., Falloon, J., 2002. The effect of garlic supplements on the pharmacokinetics of saquinavir. Clin. Infect. Dis. 34, 234-238.
PT Eisai Indonesia, 1995. Medicinal Herb Index in Indonesia.
Rendic, S., DiCarlo, F.J., 1997. Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors. Drug Metab. Rev. 29, 413-580.
Riley, R.J., Howbrook, D., 1998. In vitro analysis of the activity of the major human hepatic CYP enzymes (CYP3A4) using [N-methyl-[.sup.14]C]-erythromycin. J. Pharmacol. Toxicol. Met. 38, 189-193.
Rodrigues, D., 1996. Measurement of human liver microsomal cytochrome P450 2D6 activity using [O-methyl-[.sup.14]C]dextromethorphan as substrate. In: Johnson, E.F., Waterman, M.R. (Eds.), Cytochrome P450, Part B. Academic Press, New York, pp. 186-195.
Rosenblat, M., Belinky, P., Vaya, J., Levy, R., Hayek, T., Coleman, R., Merchav, S., Aviram, M., 1999. Macrophage enrichment with the isoflavan glabridin inhibits NADPH oxidase-induced cell-mediated oxidation of low density lipoprotein: a possible role for protein kinase C. J. Biol. Chem. 274, 13790-13799.
Sastroamidjojo, S., 1997. Tumbuh-tumbuhan yang dipergunakan sebagai obat asli Indonesia. In: Tjokronegoro, A. (Ed.), Obat Asli Indonesia. Dian Rakyat, Indonesia, pp. 27-266.
Taylor, J.R., Wilt, V.M., 1999. Probable antagonism of warfarin by green tea. Ann. Pharmacother. 33, 426-428.
Tsukamoto, S., Tomise, K., Miyakawa, K., Cha, B.C., Abe, T., Hamada, T., Hirota, H., Ohta, T., 2002. CYP3A4 inhibitory activity of new bisalkaloids, dipiperamides D and E, and cognates from white pepper. Bioorg. Med. Chem. 10, 2981-2985.
T. Usia (a), H. Iwata (a,b), A. Hiratsuka (c), T. Watabe (a), S. Kadota (a), Y. Tezuka (a,d,*)
(a) Institute of Natural Medicine, Toyama Medical and Pharmaceutical University, 2630-Sugitani, Toyama 930-0194, Japan
(b) Kashima Laboratory, Mitsubishi Chemical Safety Institute Ltd., 14-Sunayama, Ibaraki 314-0255, Japan
(c) Tokyo University of Pharmacy and Life Science, 1432-I-Horinouchi, Tokyo 192-0392, Japan
(d) 21st Century COE Program, Toyaina Medical and Pharmaceutical University, 2630-Sugitani, Toyama 930-0194, Japan
Received 22 December 2003; accepted 6 June 2004
*Corresponding author. Institute of Natural Medicine, Toyama Medical and Pharmaceutical University, 2630-Sugitani, Toyama 930-0194, Japan Tel.: 81 76 434 7627; fax: 81 76 434 5059.
E-mail address: email@example.com (Y. Tezuka).
Table 1. Indonesian medicinal plants, their families, parts used, local names, therapeutic applications, and voucher specimen numbers Part Plant name Family used Local name Alpinia galanga (L.) SWARTZ Zingiberaceae Rhizome Laos Alstonia scholaris (L.) R.BR. Apocynaceae Bark Pulai Alstonia scholaris (L.) R.BR. Apocynaceae Leaf Pulai Alyxia reinwardtii BL. Apocynaceae Bark Pulosari Amomum compactum SOLAND ex Zingiberaceae Fruit Kapulaga MATON Amomum compactum SOLAND ex Zingiberaceae Rhizome Kapulaga MATON Andrographis paniculata Acanthaceae Aerial Sambiloto (BURM. F.) NEES part Catharanthus roseus (L.) G. DON Apocynaceae Aerial Tapak dara part Cinnamomum burmani NEES ex BL. Lauraceae Bark Kayu manis Curcuma aeruginosa ROXB. Zingiberaceae Rhizome Temu ireng Curcuma heyneana VAL & V. ZIJP Zingiberaceae Rhizome Temu giring Curcuma xanthorrhiza ROXB. Zingiberaceae Rhizome Temu lawak Cymbopogon nardus (L.) RENDLE Gramineae Aerial Sere part Foeniculum vulgare MILL. Umbelliferae Seed Adhas Glycyrrhiza glabra L. Leguminosae Stem Kayu legi Melaleuca leucadendron L. Myrtaceae Leaf Kayu putih Piper cubeba L. Piperaceae Fruit Kemuk us Piper nigrum L. Piperaceae Fruit Marica putih Piper nigrum L. Piperaceae Leaf Marica putih Punica granatum L. Punicaceae Fruit Delima putih Rheum palmatum L. Polygonaceae Root Klembak Santalum album L. Santalaceae Wood Kayu cendana Sericocalyx crispus (L.) BREMEK Acanthaceae Leaf Keji beling Strychnos ligustrina BL. Loganiaceae Leaf Bidara laut Strychnos ligustrina BL. Loganiaceae Wood Bidara laut Syzygium aromaticum (L.) Myrtaceae Flower Cengkeh MERR. & PERRY Tamarindus indica L. Leguminosae Fruit Asem Tinospora crispa (L.) DIELS Menispermaceae Stem Brotowali Zingiber aromaticum VAL Zingiberaceae Rhizome Lempuyang wangi Zingiber cassumunar ROXB. Zingiberaceae Rhizome Bengle Plant name Therapeutic application TMPW No. Alpinia galanga (L.) SWARTZ Stomachic, anorexia 22261 Alstonia scholaris (L.) R.BR. Fever, anorexia, nephritis, 22262 diabetes, malaria, hypertension Alstonia scholaris (L.) R.BR. Beri-beri, syphilis, 22263 diabetes Alyxia reinwardtii BL. Fever, gastritis, 22264 albuminuria, whooping cough, carminative, leucorrhea, gonorrhea, menstrual disorder Amomum compactum SOLAND ex Cough, tonsillitis, 22265 MATON menstrual disorder, colic, influenza, gastritis Amomum compactum SOLAND ex Tonic, fever 22266 MATON Andrographis paniculata Diabetes, gonorrhea, 22267 (BURM. F.) NEES syphilis, tonsillitis, epilepsy, diphtheria, fever, typhus, tonic Catharanthus roseus (L.) G. DON Diabetes, cancer, malaria, 22268 hypertension Cinnamomum burmani NEES ex BL. Diarrhea, malaria 22269 Curcuma aeruginosa ROXB. Anthelmintic, obesity, 22270 scabies, rheumatism Curcuma heyneana VAL & V. ZIJP Anthelmintic 22271 Curcuma xanthorrhiza ROXB. Anticonvulsant, hemorrhoid, 22272 malaria, diarrhea, anorexia, gastritis, anemia, jaundice Cymbopogon nardus (L.) RENDLE Diaphoretic, body warming 22273 Foeniculum vulgare MILL. Albuminuria, insomnia, 22274 menstrual disorder Glycyrrhiza glabra L. Hepatitis, tonic 22275 Melaleuca leucadendron L. Vertigo, anticonvulsant, 22276 tooth-ache, rheumatism Piper cubeba L. Dysentery, gonorrhea 22277 Piper nigrum L. Carminative, hypertension, 22278 dyspnea Piper nigrum L. Tooth-ache 22279 Punica granatum L. Leucorrhea, constipation, 22280 diarrhea, dysentery Rheum palmatum L. Tonic, stomach-ache 22281 Santalum album L. Dysentery, asthma, fever, 22282 gonorrhea Sericocalyx crispus (L.) BREMEK Diabetes, renal calculus, 22283 vesical calculus Strychnos ligustrina BL. Antidote, depurative, 22284 stomachic Strychnos ligustrina BL. Anthelmintic, boil, chancre, 22285 depurative, antidote for snake poisoning Syzygium aromaticum (L.) Cold, cough 22286 MERR. & PERRY Tamarindus indica L. Fever, laxative 22287 Tinospora crispa (L.) DIELS Fever, diuretic, tonic, 22288 diabetes Zingiber aromaticum VAL Cholescystopathy, whooping 22289 cough, jaundice, arthritis, anorexia, cold, cholera, anemia, malaria, rheumatism, abdominalgia Zingiber cassumunar ROXB. Obesity, vertigo, 22290 constipation, cold, jaundice, anticonvulsant, rheumatism Table 2. I[C.sub.50] values of the Indonesian medicinal plants on the metabolism mediated by CYP3A4 and CYP2D6 I[C.sub.50] value ([micro]g/ml) Plant name CYP3A4 CYP2D6 MeOH-soluble fraction Als. scholaris bark NT 222 Aly. reinwardtii 447 NT An. paniculata 102 86 Ca. roseus NT 11 Ci. burmani NT 1203 Cu. heyneana 271 NT Cy. nardus 370 NT G. glabra 345 515 Pi. cubeba 53 NT Pi. nigrum fruit 29 315 Pi. nigrum leaf 25 146 Pu. granatum 35 32 R. palmatum 467 385 Sa. album 337 886 St. ligustrina leaf NT 302 St. ligustrina wood NT 637 Sy. aromaticum 219 249 Ti. crispa 428 488 Z. aromaticum 102 693 EtOAc-soluble fraction Pi. cubeba 332 NT Pi. nigrum fruit 223 344 Pi. nigrum leaf 240 NT Z. aromaticum 376 NT NT not tested.
|Printer friendly Cite/link Email Feedback|
|Author:||Usia, T.; Iwata, H.; Hiratsuka, A.; Watabe, T.; Kadota, S.; Tezuka, Y.|
|Publication:||Phytomedicine: International Journal of Phytotherapy & Phytopharmacology|
|Article Type:||Clinical report|
|Date:||Jan 1, 2006|
|Previous Article:||Bioassay-guided isolation of a vasorelaxant active compound from Kaempferia galanga L.|
|Next Article:||Tinospora cordifolia induces enzymes of carcinogen/drug metabolism and antioxidant system, and inhibits lipid peroxidation in mice.|